Skip to main content
SpringerLink
Log in

The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action

  • Conference paper
Interferons: Mechanisms of Action and Role in Cancer Therapy

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Neuroendocrine tumours of the gastrointestinal tract and pancreas are rather rare tumours with an overall incidence of 0.9 per 100,000 people. The tumours derive from endocrine cells and are generally highly differentiated, showing production of various amines and peptides. Neuroendocrine tumours of the pancreas display clinical syndromes related to hormone production such as the Zollinger-Ellison syndrome due to increased gastrin secretion, hypoglycaemic symptoms due to insulin overproduction, and the glucagonoma syndrome due to glucagon production. There also exists a group of tumours, the so-called “non-functioning” tumours, which produce hormones that do not cause any definite clinical syndrome [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eriksson B, Öberg K, Andersson T, Arnberg H, Lindgren PG, Lörelius LE, Lundqvist G, Magnusson A, Wide L, Wilander E: Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Int Med 1990 (228):103–113

    Article  CAS  Google Scholar 

  2. Norheim I, Öberg K, Theodorsson-Norheim E et al: Malignant carcinoid tumours; An analysis of 103 patients with regard to tumour localization, hormone production and survival. Ann Surg 1987 (206):115–125

    Article  PubMed  CAS  Google Scholar 

  3. Davis Z, Moertel CG, Mc llrath DC: The malignant carcinoid syndrome. Surg Gynecol Obstet 1973 (137):637–644

    PubMed  CAS  Google Scholar 

  4. Goodwin JD: Carcinoid tumors: An analysis of 2837 cases. Cancer 1975 (36): 560–569

    Article  Google Scholar 

  5. Moertel CG, Sauer WG, Dockerty MB, Baggentoss AH: Life history of the carcinoid tumor of the small intestine. Cancer 1961 (14): 901–912

    Article  PubMed  CAS  Google Scholar 

  6. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Öberg K: Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990 (65): 1883–1890

    Article  PubMed  CAS  Google Scholar 

  7. Moertel CG: An odyssey in the land of small tumors. J Clin Oncol 1987 (5): 1503

    Google Scholar 

  8. Moertel CG, Hanley JA, Johnsson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980 (303): 1189–1194

    Article  PubMed  CAS  Google Scholar 

  9. Öberg K, Eriksson B: Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 1989 (28): 425–431

    Article  PubMed  Google Scholar 

  10. Öberg K, Norheim I, Lundqvist G, Wide L: Cytotoxic treatment in patients with malignant carcinoid tumors. Respons to streptozocin alone or in combination with 5-FU. Acta Oncol 1987 (26): 429–432

    Article  PubMed  Google Scholar 

  11. Norheim I, Öberg K, Alm G: Treatment of malignant carcinoid tumors; a randomized controlled study of streptozocin plus 5-FU and human leucocyte interferon. Eur J Cancer Clin Oncol 1989 (25):1475–1479

    Article  PubMed  Google Scholar 

  12. Moertel CG, Hanley JA: Combination therapy trials in metastatic carcinoid tumors and the malignant carcinoid syndrome. Cancer Clin Trials 1970 (2): 327–334

    Google Scholar 

  13. Eriksson B, Öberg K, Andersson T et al: Treatment of malignant endocrine pancreatic tumours with a new long acting somatostatin analogue SMS 201–995. Scand J Gastroenterol 1988 (23):508

    Article  PubMed  CAS  Google Scholar 

  14. Öberg K, Norheim I, Lundqvist G, Wide L: Treatment of the carcinoid syndrome with SMS 201–995, a somatostatin analogue. Scand J Gastroenterol 1986 (21):191–192

    Article  Google Scholar 

  15. Kvols LK, Moertel CG, O’Connell MS et al: Treatment of malignant carcinoid syndrome evaluation of a long acting somatostatin analogue. New Engl J Med 1986 (315): 663–666

    Article  PubMed  CAS  Google Scholar 

  16. Quesada JR, Talpaz M, Gutterman JU: Interferons in hematological malignancies. In: Baron S, Dianzani R, Stanton GJ, Fleischman WR Jr (eds) The Interferon System. University of Texas Press, Austin 1987 pp 486–495

    Google Scholar 

  17. Bonnem E: Interferon: Potential use in solid tumours. In: Baron S, Dianzani R, Stanton GJ, Fleischman WR Jr (eds) The Interferon System. University of Texas Press, Austin 1987 pp 506–516

    Google Scholar 

  18. Öberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983 (309): 129–133

    Article  PubMed  Google Scholar 

  19. Öberg K, Norheim I, Lind E. et al: Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treatm Rep 1986 (70):1297–1304

    Google Scholar 

  20. ×berg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E: Treatment of malignant tumors with recombinant interferon alpha-2b (Intron-A); Development of neutralizing interferon and possible loss of antitumor activity. JNCI 1989 (81): 531–535

    Google Scholar 

  21. Eriksson B, Öberg K, Alm G, et al: Treatment of malignant endocrine pancreatic tumours with human leukocyte interferon. Lancet 1986 (2): 1307–1309

    Article  PubMed  CAS  Google Scholar 

  22. Öberg K, Lindström H, Alm G, Lundqvist G: Successful treatment of therapy-resistant pancreatic cholera with human leukocyte interferon. Lancet 1985 (1):725–727

    Article  PubMed  Google Scholar 

  23. Tiensuu Janson E, Kauppinen HL, Öberg K: A phase II trial with alpha-IFN and natural gamma-IFN in patients with advanced stages of malignant carcinoid tumours. J Interferon Res 1990 (10 suppl 1):128

    Google Scholar 

  24. Tiensuu Janson E, Andersson T, Öberg K: Local ß-interferon treatment in patients with neuroendocrine gut and pancreatic tumours — A preliminary report. J Interferon Res 1990 (10 suppl 1):128

    Google Scholar 

  25. Moertel C, Rubin J, Kvols LK: Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leucocyte A interferon. J Clin Oncol 1989 (7):865–868

    PubMed  CAS  Google Scholar 

  26. Hansen L-E, Schrumpt E, Jacobsen MB, Kolbenstvedt AN, Kolmannskog F, Bergur A, Dolva LO: The extended experience with recombinant alpha-2b interferon with or without hepatic artery embolization in the treatment of mid-gut carcinoid tumors. Acta Oncol 1991 (in press)

    Google Scholar 

  27. Tiensuu Janson E, Alm G, Grandér D, Öberg K: A randomized controlled study of gamma-IFN alpha 2a vs gamma-IFN alpha 2a and chemotherapy in malignant carcinoid disease. J Interferon Res 1990 (10 suppl 1):127

    Google Scholar 

  28. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986 (4): 234–243

    PubMed  CAS  Google Scholar 

  29. Ronnblom L, Aim G, Öberg K: Automimmunity in carcinoid patients treated with alpha-interferon. Ann Int Med 1991 (in press)

    Google Scholar 

  30. Burman P, Totterman HT, Öberg K, Karlsson FA: Thyroid autoimmunity in patients on long-term therapy with leucocyte-derived interferon. J Clin Endocrinol Metabol 1986 (ii):1307–1309

    Google Scholar 

  31. Wilander E, Bengtsson A, Norheim I, Öberg K, Brodin E: Interferon-induced nuclear DNA alterations in malignant carcinoid tumours in vivo. JNCI 1986 (76):429–433

    PubMed  CAS  Google Scholar 

  32. Funa K, Eriksson B, Wilander E, Öberg K: Expression of chromogranin A and B mRNA in carcinoid tumors studied by in situ hybridization. Endocrinol (in press)

    Google Scholar 

  33. Grander D, Öberg K, Lundqvist M-L et al: Interferon-induced enhancement of 2′-5′-oligoadenylate synthetase in mid-gut carcinoid tumors. Lancet 1990 (336): 337–340

    Article  PubMed  CAS  Google Scholar 

  34. Andersson T, Wilander E, Eriksson B, Lindgren PG, Öberg K: Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 1990 (50): 3413–3415

    PubMed  CAS  Google Scholar 

  35. Brosjö O, Bauer HCF, Broström LA, et al: Influence of human alpha-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res 1985 (45): 5598–5602

    PubMed  Google Scholar 

  36. Funa K, Papanicolaou V, Juhlin C, Rastad J, Åkerström G, Heldin EH, Öberg K: Expression of platelet-derived growth factor ß-receptors on stromal tissue cells in carcinoid tumours. Cancer Res 1990 (50): 748–753

    PubMed  CAS  Google Scholar 

  37. Funa K, Gazdar AF, Doyle A et al: In vivo induction of ß2 microglobulin after interferon therapy on small-cell lung cancer and mid-gut carcinoid patients. Clin Immunol Immunopathol 1986 (41): 159–164

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research and Department of Internal Medicine, University Hospital, 751 85, Uppsala, Sweden

    Kjell E. Öberg

Authors
  1. Kjell E. Öberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK

    Derek Crowther

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Öberg, K.E. (1991). The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action. In: Crowther, D. (eds) Interferons: Mechanisms of Action and Role in Cancer Therapy. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76787-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76787-6_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76789-0

  • Online ISBN: 978-3-642-76787-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation